Ratings Taysha Gene Therapies, Inc.

Equities

TSHA

US8776191061

Real-time Estimate Cboe BZX Other stock markets 12:02:28 2024-04-24 pm EDT			5-day change	1st Jan Change
2.375 ^USD	-6.13%		-2.82%	+34.52%

Apr. 09	Piper Sandler Initiates Taysha Gene Therapies at Overweight Rating With $9 Price Target	MT
Mar. 21	Chardan Adjusts PT on Taysha Gene Therapies to $7 From $5 as Gene Therapy for Rett Syndrome Shows 'Sustained Benefit', Keeps Buy Rating	MT

Summary

The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company's "enterprise value to sales" ratio is among the highest in the world.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
TAYSHA GENE THERAPIES, INC.	+34.52%	473M	D+
IQVIA HOLDINGS INC.	+3.42%	43.43B	B
LONZA GROUP AG	+47.81%	41.69B	A
MODERNA, INC.	+7.82%	41.31B	B-
CELLTRION, INC.	-10.92%	27.14B	C
ICON PUBLIC LIMITED COMPANY	+8.26%	25.28B	B-
ALNYLAM PHARMACEUTICALS, INC.	-24.59%	18.47B	B
MEDPACE HOLDINGS, INC.	+29.79%	12.59B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.82%	12.33B	C+
UNITED THERAPEUTICS CORPORATION	+9.19%	11.03B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes